Close Menu

John Kraeutler, David Phillips, Felicia Williams

Sep 24, 2018

John (Jack) Kraeutler has retired from his position as Meridian Bioscience's executive chairman of the board, effective Sept. 30, 2018. Kraeutler retired as CEO of the firm last year after 25 years in that position. Meridian has appointed David Phillips as the new chairman of the board, and has also elected Felicia Williams to the board of directors and to serve on the firm's audit committee, effective September 20, 2018. Williams previously served in financial positions at Macy's and Coca-Cola.

More Like This

Aug 15, 2019

ViroGates: Mark Christian Hvidberg da Silva

Danish blood test systems developer ViroGates announced that Mark Christian Hvidberg da Silva is joining the firm as CFO, effective Oct. 1. Its former CFO, May Britt Dyvelkov, will remain at the company as vice president of accounting. da Silva joins ViroGates from management consulting firm Qvartz where he was a manager. He previously was at Novozymes and Nova Founders Capital. 

Aug 15, 2019

Aperiomics: C. Alexander Valencia

C. Alexander Valencia has joined Aperiomics as Chief Clinical Officer. He will oversee the microorganism sequencing firm's clinical test development, validations, regulatory affairs, and operations.

Prior to joining Aperiomics, Valencia served as molecular laboratory director at Cincinnati Children's Hospital Medical Center. He has experience at PerkinElmer Genomics. He holds a doctorate from Canada's Carleton University and the University of Ottawa and held post-doctoral positions in biochemistry and molecular biology at the University of North Carolina at Chapel Hill and in clinical molecular genetics at Emory University.

Aug 14, 2019

OraSure Technologies: James Datin

OraSure Technologies has appointed James Datin to its board. He will serve as a Class III director with his initial term expiring at the company's 2021 shareholders' meeting. He will serve on OraSure's audit and compensation committees. Datin is president and CEO of BioAgilytix, a global bioanalytical contract research organization which supports the development of therapeutic biologics. Prior to that, he was executive vice president and managing director at Safeguard Scientifics. 

Aug 13, 2019

Biodesix: Robert Georgantas III

Robert Georgantas III was appointed by Biodesix as its senior vice president of research and translational science. He was formerly director of immunology programs, genomics, and the Genetics Research Center of Excellence at AbbVie. Prior to that, he was a senior scientist in the department of translational sciences at Medimmune. 

Aug 09, 2019

NeoGenomics: Sharon Virag

NeoGenomics said in a document filed with the US Securities and Exchange Commission that CFO Sharon Virag has resigned from the company, effective immediately. NeoGenomics did not provide additional details. It will begin a search for her replacement "in due course," it said.

Aug 08, 2019

Accelerate Diagnostics: Jack Phillips

Tucson, Arizona-based Accelerate Diagnostics has named Jack Phillips its new COO. Phillips most recently served as president and CEO of Roche Diagnostics North America. He was senior VP and GM of Ventana Medical Systems prior to the tissue diagnostics firm being acquired by Roche in 2008.

Aug 08, 2019

Veravas: Carroll Streetman

Charleston, South Carolina-based Veravas has appointed Carroll Streetman Jr. as CEO. Streetman previously served as president at Full Spectrum Behavior Analysis and will remain on the firm's board. Prior to Full Spectrum, Streetman served as president at DiaSorin Inc. He has also served as president and managing partner of CSHC Consultants. Prior to CSHC, he was chief operating officer of HCA Healthcare.

Aug 07, 2019

Progenity: Brian Kotzin

Progenity has appointed Brian Kotzin to its board of directors. Kotzin is currently on the board of directors for Rigel, and serves as a principal fellow and senior vice president for Nektar Therapeutics. His previous roles include vice president of global clinical development and head of the inflammation therapeutic area, and vice president and head of medical sciences at Amgen. Prior to entering the life sciences industry, he held several professorships at the University of Colorado Health Sciences Center, where his research focused on immunopathogenesis of disease.

Aug 06, 2019

Invitae: Randy Scott, Sean George

Invitae announced that Randy Scott will retire as executive chairman from its board of directors effective September 1. Invitae CEO Sean George will be the board's new chairman at that time. Scott served as CEO of Invitae between 2012 and 2017, after which George took over the reins. Scott said in a statement that he plans to continue to support the Invitae team as a private investor.

Aug 05, 2019

Foundation Medicine: Priti Hegde

Priti Hegde has been appointed as CSO of Foundation Medicine, a Roche company, effective August 5. She replaces Michael Doherty, who will be retiring in September. Previously, she held various posts at Genentech, where she was most recently senior director and principal scientist in oncology biomarker development. Prior to that, she was manager of disease and biomarker transcriptomics at GlaxoSmithKline. Hegde holds a PhD in biochemical pharmacology from SUNY Buffalo and a B. Pharmacy degree from Mumbai University in India.

Aug 05, 2019

Roche Diagnostics Canada: Andrew Plank

Andrew Plank has been appointed as president and general manager of Roche Diagnostics Canada, a division of Roche. Previously, he was global VP and international business leader in Roche Diagnostics' Centralized and Point of Care Solutions division in Switzerland.

Aug 05, 2019

Fulgent Genetics: Linda Marsh

Temple City, California-based Fulgent Genetics has appointed Linda Marsh to its board of directors. Marsh currently serves as senior executive VP at AHMC Healthcare and is a board member at Apollo Medical Holdings. In addition, she is a board member of the Hospital Association of Southern California, a board member of Private Essential Access Community Hospitals, and a board member of the American Red Cross.

Aug 01, 2019

Siemens Healthineers: Bernd Montag, Michael Reitermann, Christoph Zindel

Erlangen, Germany-based Siemens Healthineers announced that Michael Reitermann, a member of the managing board responsible for its Diagnostics business segment and its regional sales and service organization, will step down from his post on Sept. 30 and leave the company.

Starting Oct. 1, the firm's CEO Bernd Montag will be responsible for the Diagnostics business segment, the Enterprise Services and Customer Services business horizontals, and for the Americas; Europe, Middle East and Africa; and Asia-Pacific regions.

Christoph Zindel, head of Diagnostic Imaging since October 2018, will become a member of its managing board effective Oct. 1. Zindel will take over responsibility for the Imaging business segment and the Advanced Therapies business segment.

Jul 30, 2019

Exagen: Chet Burrell, Tina Nova, Bruce Robertson

San Diego, California-based Exagen has appointed Chet Burrell, Tina Nova, and Bruce Robertson to its board of directors.

Burrell has held several CEO-level positions and chairmanship roles in the US for nearly 40 years. He currently serves as managing member of Sivalon Healthcare Holdings.

Nova serves as president and CEO of Decipher Biosciences, in additon to chair of the board of directors for Arena Pharmaceuticals and a member of the board of directors at Veracyte. Prior to Decipher, Nova was president and CEO of Molecular Stethoscope and served as senior VP and general manager of Illumina's oncology business unit. In addition, Nova was a founder of Genoptix (which was acquired by Novartis in 2011), where she served as president and CEO from 2000 to 2014. Prior to Genoptix, Nova was a cofounder of Novagen, and servied as its chief operating officer and president from 1994 to 2000. Before Novagen, she served as COO of Selective Genetics. 

Robertson currently serves as managing director of H.I.G. BioHealth Partners. Prior to H.I.G., he served as managing director at Toucan Capital. Before Toucan, Robertson was director of business development at IGEN international. 

Jul 29, 2019

RenalytixAI: Thomas McLain

RenalytixAI has appointed Thomas McLain its president and chief commercial officer, effective immediately. He most recently was general manager, president, CEO, and chief operating officer for Exosome Diagnostics, where led the business and commercial strategy for the ExosomeDx Prostate test. The company was acquired by Bio-Techne in August 2018. Prior to that, McLain was president and CEO of Vermillion.